Aldeyra Therapeutics Stock News

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, July 12, 2022, at 8:00 a.m. (ET) to report

Aldeyra Therapeutics Inc's (NASDAQ: ALDX) Phase 3 TRANQUILITY-2 trial of reproxalap for dry eye disease has achieved the primary endpoint. Reproxalap was statistically superior to the vehicle for ea

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provi

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today ann

Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported a post-hoc analysis from the completed Phase 3 TRANQUILITY dry eye chamber trial of reproxalap for dry eye disease. Using computer-automated grading

ALDX earnings call for the period ending March 31, 2022.

Aldeyra Therapeutics Inc. (NASDAQ:ALDX ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Joshua Reed - Chief Financial Officer Dr. Todd Brady - Chief Executive Officer Bru

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer The�

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug Pfizer, Inc.

ALDX earnings call for the period ending December 31, 2021.

Aldeyra Therapeutics' (ALDX) CEO Todd Brady on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AbbVie's Rinvoq Gets Label Expansion To Treat Ulcerative Colitis AbbVie, Inc. (NYSE: ABBV) announced 

Aldeyra Therapeutics press release (ALDX): FY GAAP EPS of -$1.07 beats by $0.02.Cash and Cash Equivalents of $229.8 Million as of December 31, 2021; Projected Cash Runway Through 2023

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today reported recent corporate highlights and financial results for the year ended December 31, 2021. “In addition to our planned completion of clinical development for reproxalap in dry eye disease, 2022 is expected to highlight data milestones for our systemic and retinal disease platform

Companies Reporting Before The Bell • TransGlobe Energy (NASDAQ: TGA ) is estimated to report earnings for its fourth quarter. • Ikena Oncology (NASDAQ: IKNA ) is projected to report earnings for its fourth quarter. • RF Industries (NASDAQ: RFIL ) is likely to report quarterly earnings at $0.04 per share on revenue of $15.84 million. • Destination XL Group (NASDAQ: DXLG ) is estimated to report quarterly earnings at $0.13 per share on revenue of $131.88 million. • Liquidia (NASDAQ: LQDA ) is projected to report quarterly loss at $0.11 per share on revenue of $3.05 million. • IMV (NASDAQ: IMV ) is projected to report quarterly loss at $0.13 per share on revenue of $50.00 thousand. • Redhill Biopharma (NASDAQ: RDHL ) is likely to report quarterly loss at $0.33 per share on revenue of $24.08 million. • Designer Brands (NYSE: DBI ) is likely to report quarterly earnings at $0.16 per share on revenue of $839.61 million. • Kirkland''s (NASDAQ: KIRK ) is expected to report quarterly earnings at $0.